The Effect of 0.01% Atropine Eye Drops on Axial Length and Refraction in Myopic Children Compared to a Control Group

Recruiting now · Phase 2

Conditions studied: Focus on Axial Length

In brief

In this study, atropine 0.01% eye drops will be given to myopic children once at night daily for 6 months as compared to a control group to see the effect on axial length and refraction

Key facts

Study ID

NCT07456488

Run by

Liaquat National Hospital & Medical College

People needed

60

Starts

2025-07-13

Expected to finish

2026-04-30

Last updated by the study team

2026-03-06

Who can join

Age: 4 and older, up to 16. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Children aged 4-16 years
• Both genders
• Myopia of baseline SER of -1.00D or more
• Astigmatism less than or equal to -2.50D
• No medical history predisposing severe myopia (e.g., Marfan syndrome, Stickler syndrome, and retinopathy of prematurity), abnormal ocular refractive anatomy (e.g., keratoconus, lenticonus, and spherophakia)
• No history of other vision-threatening ocular diseases or previous intraocular surgery.
• No current or previous use of atropine or pirenzipine, contact lenses or other forms of treatment that may affect myopia progression.

You may not qualify if…

• Astigmatism ≥ 2.5 D
• Anisometropia>1 D
• Best corrected visual acuity < 0.5 (6/12)
• Prior intraocular surgery
• Allergy to atropine eye drops
• Systemic diseases associated with myopia such as Marfan syndrome, Stickler syndrome
• History of cardiac or significant respiratory diseases
• Lack of consent for participating in the study

Where it is running

• LiaquatNHMC — Karachi, Sindh, Pakistan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.